reserpine has been researched along with Anochlesia in 106 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 5.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| " The extract at both the doses displayed a significant reduction in postural flexion, moderate decrease in tremor, muscular rigidity and postural immobility scores but do not exhibit significant lowering of hypokinesia score in reserpine induced Parkinsonian model." | 4.12 | Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. ( Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S, 2022) |
| "Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in dopaminergic development." | 3.77 | Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. ( Aizawa, M; Iwakura, Y; Mizuno, M; Namba, H; Nawa, H; Shcherbakova, K; Sotoyama, H; Wang, R; Zheng, Y, 2011) |
| " Both ASP and GLU produced a hyperthermic response in all animals, including those in which hypothermia was induced by reserpine." | 3.69 | Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats. ( Gupta, MC; Singh, J, 1997) |
| " The drug does not possess an antidepressant action proper but activates the aggressive-defensive behaviour in experimental reserpine depression and reduces the provocation-induced aggressive behaviour in experimental haloperidol depression." | 3.66 | [Psychopharmacologic spectrum of melanostatin]. ( Klusha, VE; Kozlovskaia, MM; Svirskis, ShV; Val'dman, AV, 1980) |
| " Finally, minaprine does not antagonize either oxotremorine-induced tremors or physiostigmine-induced lethality." | 3.66 | Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug. ( Bizière, K; Kan, JP; Muyard, JP; Roncucci, R; Souilhac, J, 1982) |
| "Behavioral responses in the catalepsy, open-field, and oral movements' tests were coupled with blood pressure, body weight, and striatal tyrosine hydroxylase (TH) level assessments to establish neurobiological comparisons between reserpine-induced impairments and genetic backgrounds RESULTS: Results revealed the SHR strain was more sensitive in the catalepsy test and exhibited higher TH immunoreactivity in the dorsal striatum." | 1.91 | Genetic effects in a progressive model of parkinsonism induced by reserpine. ( Anjos, PAR; de Gois, AM; Fadanni, GP; Granzotto, N; Izídio, GS; Leão, AHFF; Linder, ÁE; Pereira, AG; Santos, JR; Silva, RH, 2023) |
| "These suggest that the RES rat model of parkinsonism can be useful in improving our knowledge on the effect of aging on neurodegeneration." | 1.72 | Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. ( Bispo, JMM; Franco, HS; Gois, AM; Lins, LCRF; Marchioro, M; Melo, JEC; Mendonça, MS; Monteiro, MCN; Ribeiro, AM; Santos, JR; Santos, RS; Santos, TFO; Silva, RH, 2022) |
| "Carvacrol (CA) is a phenolic monoterpene found in essential oils of many aromatic plants that presents antioxidant and neuroprotective effects." | 1.48 | Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine. ( Andrade, RAS; Bispo, JMM; Gois, AM; Lins, LCRF; Marchioro, M; Melo, TCS; Quintans-Junior, LJ; Ribeiro, AM; Santos, JR; Silva, RH; Souza, MF, 2018) |
| " Assessment of the effects of chronic administration of Diol (20mg/kg) and L-DOPA to animals with 6-OHDA-induced PS showed that administration of Diol alleviated the symptoms of sensorimotor deficit in right limbs in rats." | 1.46 | Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models. ( Ardashov, O; Ivanova, Е; Kapitsa, I; Khazanov, V; Salakhutdinov, N; Valdman, E; Volcho, K; Voronina, TI, 2017) |
| "Here we used the animal models of extrapyramidal disorders cited above, which were performed in two distinct experiments: orofacial dyskinesia (OD)/catalepsy induced by acute reserpine and subchronic haloperidol after (experiment 1) and before (experiment 2) oral treatment with pecan shell aqueous extract (AE), a natural and promissory antioxidant." | 1.37 | Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. ( Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F, 2011) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism." | 1.33 | Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice. ( Kulkarni, SK; Kumar, A, 2006) |
| "When quercetin was combined with a subthreshold dose of L-dopa plus carbidopa, the anticatatonic effect was potentiated." | 1.32 | Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. ( Kulkarni, SK; Naidu, PS; Singh, A, 2003) |
| "Reserpine-induced catalepsy is a widely accepted animal model of Parkinson's disease." | 1.32 | FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats. ( Kulkarni, SK; Naidu, PS; Singh, A, 2003) |
| "Except for reserpine, catalepsy scores were significantly lower in A2AR KO mice than in A2AR WT mice following low doses of these cataleptogenic agents." | 1.31 | Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy. ( Costentin, J; El Yacoubi, M; Ledent, C; Parmentier, M; Vaugeois, JM, 2001) |
| "Haloperidol-induced catalepsy was inhibited by the Merz glycine site antagonists MRZ 2/570, MRZ 2/571 and MRZ 2/576 but not by another antagonist L-701,324 or the glycine site partial agonists ACPC and D-CS." | 1.30 | GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. ( Danysz, W; Karcz-Kubicha, M; Lorenz, B, 1999) |
| "The potentiation of the haloperidol catalepsy was antagonized by imipramine which displayed antiglutamatergic and antimuscarinic properties." | 1.29 | [Pharmacologic profile of n-palmitoylglycine. Its effect on reserpine and haloperidol catalepsy]. ( Vamvakidès, A, 1995) |
| "Quinpirole (1 mg/kg i." | 1.29 | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists. ( Hubbard, CA; Trugman, JM, 1993) |
| "The reserpine-induced catalepsy was attenuated by CGP 37849." | 1.29 | Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. ( Maj, J; Rogóz, Z; Skuza, G, 1993) |
| "SG treatment alone did not induce catalepsy." | 1.28 | Influences of diterpene sclareol glycol on some dopamine related behavior. ( Georgieva, JV, 1991) |
| "Melatonin was found to attenuate markedly the duration of reserpine-induced catalepsy." | 1.28 | Attenuation of reserpine-induced catalepsy by melatonin and the role of the opioid system. ( Mukherjee, S; Sandyk, R, 1989) |
| "2." | 1.26 | The interaction of clonidine with dopamine-dependent behaviour in rodents. ( Jenner, PG; Marsden, CD; Pycock, CJ, 1977) |
| "WA-335 antagonized catalepsy induced by these neuroleptics (the effect on reserpine-induced catalepsy was weakest)." | 1.26 | Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy. ( Baran, L; Maj, J; Sowińska, H, 1976) |
| "The pilocarpine-catalepsy was abolished by atropine, promethazine and nomifensine and unaffected by tricyclic antidepressants." | 1.26 | On the anticataleptic action of cyproheptadine. ( Klimek, V; Maj, J; Rawlów, A; Sarnek, J, 1976) |
| "PCA had no influence on catalepsy induced by neuroleptics from the group of butyrophenones, potentiated the cataleptic action of reserpine in the dose of 5 mg/kg, and suppressed catalepsy induced by reserpine in the dose of 10 mg/kg." | 1.25 | The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats. ( Baran, L; Sarnek, J, 1975) |
| "Maprotiline was more potent than anitriptyline and imipramine in antagonizing haloperidol-induced catalepsy as well as in suppressing muricide induced by either olfactory bulbectomy or delta-9-tetrahydrocannabinol in rats." | 1.25 | [Behavior pharmacology of maprotiline, a new antidepressant]. ( Fujiwara, M; Ibii, N; Inoue, K; Kataoka, Y; Ueki, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 68 (64.15) | 18.7374 |
| 1990's | 16 (15.09) | 18.2507 |
| 2000's | 5 (4.72) | 29.6817 |
| 2010's | 14 (13.21) | 24.3611 |
| 2020's | 3 (2.83) | 2.80 |
| Authors | Studies |
|---|---|
| Pal Roy, S | 1 |
| Kadiri, SK | 1 |
| Karkar, VV | 1 |
| Rao Konijeti, S | 1 |
| Melo, JEC | 1 |
| Santos, TFO | 1 |
| Santos, RS | 1 |
| Franco, HS | 1 |
| Monteiro, MCN | 1 |
| Bispo, JMM | 2 |
| Mendonça, MS | 1 |
| Ribeiro, AM | 4 |
| Silva, RH | 5 |
| Gois, AM | 2 |
| Marchioro, M | 2 |
| Lins, LCRF | 2 |
| Santos, JR | 5 |
| Fadanni, GP | 1 |
| Leão, AHFF | 1 |
| Granzotto, N | 1 |
| Pereira, AG | 1 |
| de Gois, AM | 1 |
| Anjos, PAR | 1 |
| Linder, ÁE | 1 |
| Izídio, GS | 2 |
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Campêlo, CLC | 1 |
| Silva, AF | 2 |
| Dierschnabel, AL | 2 |
| Pontes, A | 1 |
| Cavalcante, JS | 2 |
| Valdman, E | 1 |
| Kapitsa, I | 1 |
| Ivanova, Е | 1 |
| Voronina, TI | 1 |
| Ardashov, O | 1 |
| Volcho, K | 1 |
| Khazanov, V | 1 |
| Salakhutdinov, N | 1 |
| Souza, MF | 1 |
| Melo, TCS | 1 |
| Andrade, RAS | 1 |
| Quintans-Junior, LJ | 1 |
| El-Ghazaly, MA | 1 |
| Sadik, NA | 1 |
| Rashed, ER | 1 |
| Abd-El-Fattah, AA | 1 |
| Cunha, JA | 1 |
| Campêlo, CL | 1 |
| Leão, AH | 1 |
| Engelberth, RC | 1 |
| Abílio, VC | 1 |
| Konieczny, J | 1 |
| Lenda, T | 1 |
| Ferger, B | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Shobo, M | 1 |
| Kondo, Y | 1 |
| Yamada, H | 1 |
| Mihara, T | 1 |
| Yamamoto, N | 1 |
| Katsuoka, M | 1 |
| Harada, K | 1 |
| Ni, K | 1 |
| Matsuoka, N | 1 |
| Barcelos, RC | 2 |
| Benvegnú, DM | 2 |
| Boufleur, N | 2 |
| Pase, C | 1 |
| Teixeira, AM | 1 |
| Reckziegel, P | 2 |
| Emanuelli, T | 1 |
| da Rocha, JB | 1 |
| Bürger, ME | 2 |
| Trevizol, F | 1 |
| Pase, CS | 1 |
| Segat, HJ | 1 |
| Dias, VT | 1 |
| Dolci, GS | 1 |
| Sotoyama, H | 1 |
| Zheng, Y | 1 |
| Iwakura, Y | 1 |
| Mizuno, M | 1 |
| Aizawa, M | 1 |
| Shcherbakova, K | 1 |
| Wang, R | 1 |
| Namba, H | 1 |
| Nawa, H | 1 |
| Maxia, A | 1 |
| Frau, MA | 1 |
| Foddis, C | 1 |
| Lancioni, MC | 1 |
| Kasture, V | 1 |
| Kasture, S | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Singh, A | 2 |
| Naidu, PS | 2 |
| Kulkarni, SK | 3 |
| BARUK, H | 1 |
| LAUNAY, J | 1 |
| BERGES, J | 1 |
| WINDLE, WF | 1 |
| CAMMERMEYER, J | 1 |
| JORALEMON, J | 1 |
| SMART, JO | 1 |
| FERINGA, ER | 1 |
| MCQUILLEN, MP | 1 |
| BILY, J | 1 |
| BOISSIER, JR | 3 |
| SIMON, P | 3 |
| NAKAJIMA, H | 1 |
| GRANDJEAN, JL | 1 |
| LHUILLIER, J | 1 |
| THUILLIER, J | 1 |
| Kumar, A | 1 |
| Val'dman, AV | 1 |
| Kozlovskaia, MM | 1 |
| Klusha, VE | 1 |
| Svirskis, ShV | 1 |
| Balsara, JJ | 1 |
| Gada, VP | 1 |
| Nandal, NV | 1 |
| Chandorkar, AG | 1 |
| Moss, DE | 1 |
| McMaster, SB | 1 |
| Rogers, J | 1 |
| Langwiński, R | 1 |
| Fidecka, S | 1 |
| Bizière, K | 2 |
| Kan, JP | 2 |
| Souilhac, J | 1 |
| Muyard, JP | 1 |
| Roncucci, R | 2 |
| Namba, MM | 2 |
| Quock, RM | 2 |
| Malone, MH | 2 |
| Avramova, P | 1 |
| Dryanovska, L | 1 |
| Ilarionov, Y | 1 |
| Tobe, A | 1 |
| Yoshida, Y | 1 |
| Ikoma, H | 1 |
| Tonomura, S | 1 |
| Kikumoto, R | 1 |
| Baran, L | 5 |
| Przegaliński, E | 2 |
| Vamvakidès, A | 5 |
| Kikuchi, T | 1 |
| Tottori, K | 1 |
| Uwahodo, Y | 1 |
| Hirose, T | 1 |
| Miwa, T | 1 |
| Oshiro, Y | 1 |
| Morita, S | 1 |
| Hubbard, CA | 1 |
| Trugman, JM | 1 |
| Subarnas, A | 1 |
| Tadano, T | 1 |
| Oshima, Y | 1 |
| Kisara, K | 2 |
| Ohizumi, Y | 1 |
| Maj, J | 7 |
| Skuza, G | 2 |
| Rogóz, Z | 2 |
| Hauber, W | 1 |
| Münkle, M | 1 |
| Singh, J | 1 |
| Gupta, MC | 1 |
| Fink-Jensen, A | 1 |
| Nielsen, EB | 1 |
| Hansen, L | 1 |
| Scheideler, MA | 1 |
| Almeida, RN | 1 |
| Navarro, DS | 1 |
| de Assis, TS | 1 |
| de Medeiros, IA | 1 |
| Thomas, G | 1 |
| Karcz-Kubicha, M | 1 |
| Lorenz, B | 1 |
| Danysz, W | 1 |
| Rivas, E | 1 |
| de Ceballos, ML | 1 |
| Nieto, O | 1 |
| Fontenla, JA | 1 |
| Shiozaki, S | 1 |
| Ichikawa, S | 1 |
| Nakamura, J | 1 |
| Kitamura, S | 1 |
| Yamada, K | 1 |
| Kuwana, Y | 1 |
| Sikiric, P | 1 |
| Marovic, A | 1 |
| Matoz, W | 1 |
| Anic, T | 1 |
| Buljat, G | 1 |
| Mikus, D | 1 |
| Stancic-Rokotov, D | 1 |
| Separovic, J | 1 |
| Seiwerth, S | 1 |
| Grabarevic, Z | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Ziger, T | 1 |
| Sebecic, B | 1 |
| Zoricic, I | 1 |
| Turkovic, B | 1 |
| Aralica, G | 1 |
| Perovic, D | 1 |
| Duplancic, B | 1 |
| Lovric-Bencic, M | 1 |
| Rotkvic, I | 1 |
| Mise, S | 1 |
| Jagic, V | 1 |
| Hahn, V | 1 |
| Fukuzaki, K | 1 |
| Kamenosono, T | 1 |
| Nagata, R | 1 |
| El Yacoubi, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Costentin, J | 1 |
| Vaugeois, JM | 1 |
| Dessaigne, S | 1 |
| Scotto, AM | 1 |
| Guigues, M | 1 |
| Matsui, Y | 1 |
| Deguchi, T | 1 |
| Kruse, H | 1 |
| Hoffmann, I | 2 |
| Gerhards, HJ | 1 |
| Leven, M | 1 |
| Schacht, U | 1 |
| Pycock, CJ | 1 |
| Jenner, PG | 1 |
| Marsden, CD | 1 |
| Ginos, JZ | 1 |
| Stevens, JM | 1 |
| Nichols, DE | 1 |
| Sato, M | 1 |
| Puech, AJ | 1 |
| Chermat, R | 1 |
| Poirier, LJ | 1 |
| Péchadre, JC | 1 |
| Larochelle, L | 1 |
| Dankova, J | 1 |
| Boucher, R | 1 |
| Sowińska, H | 3 |
| Uspenskiĭ, AE | 1 |
| Korobov, NV | 1 |
| Sarnek, J | 3 |
| Klimek, V | 1 |
| Rawlów, A | 1 |
| Gogerty, JH | 1 |
| Penberthy, C | 1 |
| Iorio, LC | 1 |
| Trapold, JH | 1 |
| Shoji, T | 1 |
| Sakurada, S | 1 |
| Doggett, NS | 1 |
| Case, G | 1 |
| Binet, P | 1 |
| Miocque, M | 1 |
| Roux, M | 1 |
| Rinjard, P | 1 |
| Ueki, S | 3 |
| Fujiwara, M | 1 |
| Inoue, K | 1 |
| Kataoka, Y | 1 |
| Ibii, N | 1 |
| Ahlenius, S | 1 |
| Wijkström, A | 1 |
| Georgieva, JV | 1 |
| Sandyk, R | 2 |
| Fisher, H | 1 |
| Mukherjee, S | 1 |
| Arnt, J | 1 |
| Yamaguchi, K | 1 |
| Nabeshima, T | 1 |
| Kameyama, T | 1 |
| Asselin, AA | 1 |
| Humber, LG | 1 |
| Voith, K | 1 |
| Metcalf, G | 1 |
| Worms, P | 1 |
| Wermuth, CG | 1 |
| Coudert, P | 1 |
| Rubat, C | 1 |
| Couquelet, JM | 1 |
| Bastide, J | 1 |
| Olgiati, VR | 1 |
| Algeri, S | 1 |
| Stramentinoli, G | 1 |
| Burak, K | 1 |
| Lipnicka, U | 1 |
| Orszańska, H | 1 |
| Rykowski, Z | 1 |
| Witkiewicz, K | 1 |
| Wrzesień, J | 1 |
| Bogdal, M | 1 |
| Krzywasiński, L | 1 |
| Borkowska, B | 1 |
| Sayers, AC | 1 |
| Handley, SL | 1 |
| Vagne, A | 1 |
| Vigier, J | 1 |
| Boucherle, A | 1 |
| Johnson, AM | 1 |
| Vigouret, JM | 1 |
| Loew, DM | 1 |
| Auclair, M | 1 |
| Auclair, MC | 1 |
| Thevenot, R | 1 |
| Villeneuve, A | 1 |
| Larousse, C | 1 |
| Boyaner, HG | 1 |
| Radouco-Thomas, S | 1 |
| Fog, R | 2 |
| Lal, S | 1 |
| Sourkes, TL | 1 |
| Missala, K | 1 |
| Belendiuk, G | 1 |
| Ogawa, N | 2 |
| Watanabe, S | 2 |
| Gomita, Y | 2 |
| Araki, Y | 2 |
| Young, RL | 1 |
| Albano, RF | 1 |
| Charnecki, AM | 1 |
| Opar, GE | 1 |
| Sheppard, H | 1 |
| Cashin, CH | 1 |
| Sutton, S | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Ahtee, L | 1 |
| Furukawa, T | 1 |
| Ono, N | 1 |
| Hanabusa, Y | 1 |
| Kushiku, K | 1 |
| Pakkenberg, H | 1 |
| Pálosi, E | 1 |
| Mészáros, C | 1 |
| Szporny, L | 1 |
| Julou, L | 1 |
| Nieschulz, O | 1 |
| Schmersahl, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for reserpine and Anochlesia
| Article | Year |
|---|---|
On stereotypy and catalepsy: studies on the effect of amphetamines and neuroleptics in rats.
Topics: Amphetamine; Animals; Basal Ganglia; Caffeine; Catalepsy; Cocaine; Compulsive Behavior; Corpus Stria | 1972 |
105 other studies available for reserpine and Anochlesia
| Article | Year |
|---|---|
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antipar | 2022 |
Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism.
Topics: Aging; Animals; Catalepsy; Disease Models, Animal; Dopamine; Male; Motor Activity; Motor Disorders; | 2022 |
Genetic effects in a progressive model of parkinsonism induced by reserpine.
Topics: Animals; Behavior, Animal; Catalepsy; Male; Parkinsonian Disorders; Rats; Rats, Inbred Lew; Rats, In | 2023 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
Exposure to an enriched environment facilitates motor recovery and prevents short-term memory impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in mice.
Topics: Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Catalepsy; Corpus Striatum; Disease | 2017 |
Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models.
Topics: Animals; Antiparkinson Agents; Catalepsy; Cyclohexanols; Disease Models, Animal; Male; Mice; Mice, I | 2017 |
Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine.
Topics: Analysis of Variance; Animals; Antiparasitic Agents; Antipsychotic Agents; Catalepsy; Cymenes; Disea | 2018 |
Neuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apoptosis; Behavior, Animal; Brain Chemistry; Catalepsy; Combined Mod | 2015 |
Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Cognition; Data Interpretation, Statistical; Dyskinesia | 2013 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Mod | 2013 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antipsychotic Agents; Apomorphine; Bod | 2010 |
Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats.
Topics: Animals; Catalepsy; Dietary Supplements; Disease Models, Animal; Fish Oils; Male; Movement Disorders | 2011 |
Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Topics: Animals; Basal Ganglia Diseases; Carya; Catalepsy; Disease Models, Animal; Haloperidol; Male; Moveme | 2011 |
Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Biomarkers; Catalepsy; Dis | 2011 |
Ethanolic extract of Rubia peregrina L. (Rubiaceae) inhibits haloperidol-induced catalepsy and reserpine-induced orofacial dyskinesia.
Topics: Animals; Catalepsy; Ethanol; Haloperidol; Male; Movement Disorders; Plant Extracts; Rats; Reserpine; | 2012 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Topics: Animals; Antiparkinson Agents; Catalepsy; Catechol O-Methyltransferase Inhibitors; Levodopa; Male; M | 2003 |
[A new form of experimental catatonia: experimental catatonia induced by reserpine].
Topics: Antihypertensive Agents; Catalepsy; Catatonia; Reserpine; Secologanin Tryptamine Alkaloids | 1956 |
Effects of reserpine in animals, especially primates.
Topics: Animals; Catalepsy; Movement Disorders; Primates; Reserpine | 1956 |
[EFFECT OF VARIOUS PHARMACOLOGICAL AGENTS ON CATALEPTIC SYMPTOMS IN CATATONIC STUPOR].
Topics: Amphetamine; Amphetamines; Catalepsy; Catatonia; Chlorpromazine; Humans; Reserpine; Stupor | 1963 |
[EXPERIMENTAL EQUIVALENTS OF THE NEUROLOGIC SYNDROME OF NEUROLEPTICS].
Topics: Antipsychotic Agents; Catalepsy; Catatonia; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Neuro | 1964 |
[EXPERIMENTAL ANTAGONISM OF CHLORPROMAZINE AND THIORIDAZINE IN RELATION TO CERTAIN EFFECTS OF LYSERGIDE].
Topics: 5-Hydroxytryptophan; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Humans; Hypothermia; Lysergi | 1964 |
FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
Topics: Animals; Antiparkinson Agents; Catalepsy; Drug Therapy, Combination; Female; Immunosuppressive Agent | 2003 |
Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice.
Topics: Animals; Catalepsy; Female; Haloperidol; Male; Medicine, Ayurvedic; Mice; Parkinsonian Disorders; Ph | 2006 |
[Psychopharmacologic spectrum of melanostatin].
Topics: Aggression; Amantadine; Animals; Behavior, Animal; Biogenic Amines; Brain Chemistry; Catalepsy; Cats | 1980 |
Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Blepharoptosis; Catalepsy; Fenclonine; | 1984 |
Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.
Topics: Animals; Antiparkinson Agents; Catalepsy; Dose-Response Relationship, Drug; Dronabinol; Drug Synergi | 1981 |
Central action of narcotic analgesics. IX. Participation of serotonin in the development of tolerance to cataleptogenic effects of morphine in rats.
Topics: 5-Hydroxytryptophan; Animals; Catalepsy; Drug Interactions; Drug Tolerance; Fenclonine; Humans; Male | 1981 |
Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Catalepsy; Dextroamphetamine; Drug Evaluation; Dru | 1982 |
Narcotic antagonist potentiation of L-DOPA in the reversal of reserpine induced catalepsy.
Topics: Animals; Catalepsy; Drug Synergism; Humans; Levodopa; Male; Mice; Naloxone; Naltrexone; Narcotic Ant | 1980 |
Effects of narcotic antagonists on L-dopa reversal of reserpine-induced catalepsy and blepharoptosis in mice.
Topics: Animals; Blepharoptosis; Catalepsy; Drug Antagonism; Drug Synergism; Humans; Kinetics; Levodopa; Mal | 1981 |
Synthesis and pharmacologic study of the esters of carbamic and carbonic acids with 1-phenyl-2,2-dimethyl-3-dialkylamino-1-propanols. Part 2.
Topics: Amines; Animals; Antidepressive Agents; Carbamates; Carbonates; Catalepsy; Chemical Phenomena; Chemi | 1981 |
Pharmacological evaluation of 2-(4-methylaminobutoxy)diphenylmethane hydrochloride (MCI-2016), a new psychotropic drug with antidepressant activity.
Topics: Aggression; Animals; Antidepressive Agents; Behavior, Animal; Benzhydryl Compounds; Catalepsy; Catec | 1981 |
Psychopharmacological profile of mesterolone.
Topics: Animals; Behavior, Animal; Body Temperature; Catalepsy; Dihydrotestosterone; Humans; Levodopa; Male; | 1981 |
[Pharmacologic profile of n-palmitoylglycine. Its effect on reserpine and haloperidol catalepsy].
Topics: Animals; Catalepsy; Glycine; Haloperidol; Male; Mice; Palmitic Acids; Rats; Reserpine | 1995 |
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Catalepsy; Corpus Striatu | 1995 |
Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists.
Topics: Animals; Behavior, Animal; Catalepsy; Dopamine Agents; Locomotion; Methyltyrosines; Posture; Rats; R | 1993 |
Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from Lobelia inflata leaves.
Topics: Animals; Antidepressive Agents; Apomorphine; Blepharoptosis; Catalepsy; Central Nervous System; Dose | 1993 |
Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Topics: 2-Amino-5-phosphonovalerate; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Antipsychotic Agen | 1993 |
The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Dizocilpine Maleate; Dopamine; gamma-Aminobutyric A | 1996 |
Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesia; Analgesics, Opioid; Animals; Aspartic Acid; Body Temperatur | 1997 |
Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Avoidance Learning; Behavior, | 1998 |
Antidepressant effect of an ethanolic extract of the leaves of Cissampelos sympodialis in rats and mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Blepharoptosis; | 1998 |
GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Catalepsy; Cyclopentanes; Drug Evaluation, Prec | 1999 |
In vivo effects of new inhibitors of catechol-O-methyl transferase.
Topics: Animals; Benzylidene Compounds; Carbidopa; Catalepsy; Catechol O-Methyltransferase Inhibitors; Enzym | 1999 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychoti | 1999 |
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dextroamphetamine; Dopamine Agents; Dopam | 1999 |
A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine.
Topics: Animals; Anti-Ulcer Agents; Behavior, Animal; Body Temperature; Catalepsy; Hypothermia; Male; Mice; | 1999 |
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Catalepsy; Dopamine Agonists; Indoles; Macaca fascicul | 2000 |
Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy.
Topics: Animals; Benzazepines; Catalepsy; Dopamine Antagonists; Haloperidol; Male; Mice; Mice, Knockout; Mus | 2001 |
[Lithium modifications of the cataleptogenic properties of various neuroleptic drugs in the rat].
Topics: Animals; Antipsychotic Agents; Catalepsy; Drug Synergism; Female; Haloperidol; Humans; Lithium; Phen | 1978 |
Cataleptic action of nitrazepam and brain dopamine function in mice.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Catalepsy; Chlorpromazine; Dop | 1977 |
Pharmacological and biochemical studies with three metabolites of nomifensine.
Topics: Animals; Antidepressive Agents; Body Temperature; Brain; Catalepsy; Dopamine; Drug Interactions; Ele | 1977 |
The interaction of clonidine with dopamine-dependent behaviour in rodents.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Clonidine; Corpus Striatum; Dextroamphetamine; Do | 1977 |
Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice.
Topics: Animals; Behavior, Animal; Catalepsy; Dopamine; Humans; Male; Mice; Naphthalenes; Posture; Reserpine | 1979 |
[Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author's transl)].
Topics: Aminophylline; Animals; Anticonvulsants; Body Temperature; Catalepsy; Cats; Central Nervous System; | 1979 |
Bromocriptin and methylergometrine: pharmacological approach of the mechanism of their central effects.
Topics: Animals; Behavior, Animal; Body Temperature; Bromocriptine; Catalepsy; Drug Interactions; Ergolines; | 1977 |
Stereotaxic lesions and movement disorders in monkeys.
Topics: Animals; Brain; Brain Mapping; Butyrophenones; Catalepsy; Catatonia; Cerebellum; Chorea; Haplorhini; | 1975 |
Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy.
Topics: Amantadine; Animals; Anthracenes; Catalepsy; Drug Synergism; Female; Humans; Levodopa; Male; Physost | 1976 |
[Facilitation of the effects of L-DOPA by alpha-methyldopa].
Topics: Animals; Blood Pressure; Catalepsy; Cats; Dopamine; Drug Interactions; Drug Therapy, Combination; Ha | 1976 |
On the anticataleptic action of cyproheptadine.
Topics: Animals; Atropine; Catalepsy; Clomipramine; Cyproheptadine; Desipramine; Female; Fluphenazine; Human | 1976 |
Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).
Topics: Aggression; Animals; Appetite Depressants; Blood Glucose; Body Temperature; Brain Chemistry; Catalep | 1975 |
[Effect of beta-phenylethylamine derivatives on the central nervous system. III. Motor activity changes in mice due to the intracerebral administration of metaraminol].
Topics: Animals; Blepharoptosis; Brain; Catalepsy; Dopamine; Humans; Hydroxydopamines; Injections, Intravent | 1975 |
Some observations on the interaction between cardiac glycosides and reserpine in the heart and central nervous system.
Topics: Animals; Blepharoptosis; Body Temperature; Brain; Cardiac Glycosides; Catalepsy; Depression, Chemica | 1975 |
The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats.
Topics: Amphetamines; Catalepsy; Fluphenazine; Humans; p-Chloroamphetamine; Pimozide; Reserpine; Serotonin; | 1975 |
[Farnesol and neuroleptics. I. Reinforcement by farnesol of the experimental cataleptigenic effect of neuroleptics].
Topics: Animals; Catalepsy; Chlorpromazine; Drug Synergism; Farnesol; Haloperidol; Humans; Rats; Reserpine; | 1975 |
[Behavior pharmacology of maprotiline, a new antidepressant].
Topics: Aggression; Amitriptyline; Animals; Anthracenes; Apomorphine; Behavior, Animal; Body Temperature; Ca | 1975 |
Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; Bridged Bicycl | 1992 |
Influences of diterpene sclareol glycol on some dopamine related behavior.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Diterpenes; Dopamine; Haloperidol; Male; Mice; Mo | 1991 |
Melatonin potentiates the effects of naloxone on reserpine-induced catalepsy in the rat.
Topics: Animals; Catalepsy; Drug Interactions; Female; Melatonin; Naloxone; Pineal Gland; Rats; Rats, Inbred | 1989 |
Attenuation of reserpine-induced catalepsy by melatonin and the role of the opioid system.
Topics: Animals; Catalepsy; Endorphins; Female; Melatonin; Nalbuphine; Naloxone; Rats; Rats, Inbred Strains; | 1989 |
Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1985 |
[Effect of GABA-linoleamide and glycine-linoleamide on catalepsy in the rat after chronic administration of reserpine].
Topics: Animals; Catalepsy; Drug Synergism; gamma-Aminobutyric Acid; Glycine; Linoleic Acids; Male; Psychotr | 1986 |
Role of dopaminergic and GABAergic mechanisms in discrete brain areas in phencyclidine-induced locomotor stimulation and turning behavior.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Caudate Nucleus; Dopamine; Globus Pallidus; Haloperidol | 1986 |
Drug design via pharmacophore identification. Dopaminergic activity of 3H-benz[e]indol-8-amines and their mode of interaction with the dopamine receptor.
Topics: Amines; Animals; Catalepsy; Corpus Striatum; Hydroxydopamines; Indoles; Male; Mice; Motor Activity; | 1986 |
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Bod | 1987 |
[Synthesis and antidepressive effects of diaryl-4,6-amino-3-pyridazine analogs of minaprine].
Topics: Animals; Antidepressive Agents; Catalepsy; Chemical Phenomena; Chemistry; Female; Male; Mice; Morpho | 1988 |
Biochemical and behavioural indices of striatal dopaminergic activity after 6-methyltetrahydropterin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1987 |
[Effect of 3 new GABA-ergics on reserpine catalepsy and apomorphine sedation in rats].
Topics: Animals; Apomorphine; Catalepsy; Drug Synergism; gamma-Aminobutyric Acid; Male; Psychotropic Drugs; | 1987 |
[Effect of glycine linoleamide on haloperidol and reserpine catalepsy in the rat].
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; | 1986 |
Synthesis of new arylanalogs of ketamine.
Topics: Amphetamine; Analgesics; Animals; Anticonvulsants; Behavior, Animal; Blepharoptosis; Body Temperatur | 1985 |
[2 new GABA-ergics (GABA-linoleamide and GABA-steatamide). On 2 experimental models of depression].
Topics: Animals; Apomorphine; Catalepsy; Depressive Disorder; Drug Synergism; gamma-Aminobutyric Acid; Human | 1985 |
A study of the role of catecholamines in the response to various central stimulants.
Topics: Amphetamine; Animals; Apomorphine; Catalepsy; Catecholamines; Central Nervous System Stimulants; Coc | 1973 |
[Action on the central nervous system of NN'-diphenylacetamidine and its salts].
Topics: Acetamides; Acetates; Amidines; Amphetamine; Animals; Body Temperature; Catalepsy; Central Nervous S | 1970 |
Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain; Bromine; Catalepsy; Dextroamphe | 1974 |
Disulfiram and the effect of catecholamines on neuroleptic-induced catalepsy in mice and rats.
Topics: Animals; Brain; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Disulfiram; Drug Antagonism; Halo | 1967 |
[Prevention of neuroleptic catalepsy by single or repeated administration of thiamine].
Topics: Animals; Catalepsy; Central Nervous System; Chlorpromazine; Humans; Male; Mice; Phenothiazines; Proc | 1967 |
Flurothyl in mice: seizure, post-convulsive behavior, and interactions with psychotropic drugs.
Topics: Amphetamine; Animals; Atropine; Behavior, Animal; Biperiden; Caffeine; Catalepsy; Central Nervous Sy | 1968 |
Effect of calcium on reserpine-induced catalepsy.
Topics: Animals; Calcium; Catalepsy; Humans; Injections, Subcutaneous; Male; Rats; Reserpine | 1971 |
Effects of aporphine and emetine alkaloids on central dopaminergic mechanisms in rats.
Topics: Alkaloids; Animals; Apomorphine; Aporphines; Behavior, Animal; Brain Chemistry; Catalepsy; Dimethyl | 1972 |
[Psychopharmacological effects of doxepin hydrochloride].
Topics: Amitriptyline; Amphetamine; Animals; Behavior, Animal; Blepharoptosis; Body Temperature; Brain Chemi | 1972 |
Regional neurochemical correlates of reserpine induced catalepsy in mouse central nervous system.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals | 1973 |
The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine.
Topics: Amantadine; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Benztropine; Brain | 1973 |
Neuroleptic and non-neuroleptic catalepsy.
Topics: Animals; Aporphines; Basal Ganglia; Butyrophenones; Catalepsy; Caudate Nucleus; Dibenzazepines; Dibe | 1973 |
8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant.
Topics: Amitriptyline; Animals; Antidepressive Agents; Blood Pressure; Body Temperature; Catalepsy; Chemical | 1973 |
Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
Topics: Amantadine; Animals; Apomorphine; Blood Pressure; Body Temperature; Brain Chemistry; Catalepsy; Chlo | 1974 |
Catalepsy and stereotypies in rats treated with methadone; relation to striatal dopamine.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Catalepsy; Corpus Striatum; Dopamine; Dose | 1974 |
The effect of amantadine on motor activity and catalepsy in rats.
Topics: Amantadine; Animals; Brain; Catalepsy; Catecholamines; Chlorpromazine; Cocaine; Desipramine; Dihydro | 1972 |
[Effects of Natulan (procarbazine hydrochloride) on the central nervous system].
Topics: Analgesics; Animals; Behavior, Animal; Benzoates; Catalepsy; Central Nervous System; Chlorpromazine; | 1971 |
[Behavioral and neuopharmacological effects of flupentixol].
Topics: Anesthetics; Animals; Antiemetics; Behavior, Animal; Body Temperature; Catalepsy; Cats; Central Nerv | 1971 |
Intracerebral lesions causing stereotyped behaviour in rats.
Topics: Amphetamine; Animals; Basal Ganglia; Behavior, Animal; Brain Injuries; Catalepsy; Catheterization; D | 1971 |
Pharmacological studies with N-3,4,5-trimethoxybenzoyl-heptamethylene imine (N-1157), a new antidepressant agent.
Topics: Amphetamine; Animals; Antidepressive Agents; Ataxia; Blood Pressure; Body Temperature; Catalepsy; Ca | 1969 |
On the interaction between neuroleptics and antiparkinson drugs.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; C | 1970 |
[On the active substances of betels].
Topics: Animals; Areca; Catalepsy; Chlorpromazine; Humans; Liver; Mice; Nicotinic Acids; Parasympathomimetic | 1967 |